Options for the management of mucosal candidiasis in patients with AIDS and HIV infection

Pharmacotherapy

Volumn 19, Issue 1 I, 1999, Pages 76-87

  Vazquez, Jose A ^a,b  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Henry Ford Health System Division of Infectious Diseases   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ANTACID AGENT; ANTIFUNGAL AGENT; ASTEMIZOLE; BREATH AWAY; CIMETIDINE; CISAPRIDE; CLOTRIMAZOLE; CYCLOSPORIN; DIDANOSINE; DIGOXIN; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; KETOCONAZOLE; LANSOPRAZOLE; MIDAZOLAM; MK 0911; NYSTATIN; OMEPRAZOLE; POSACONAZOLE; PROTON PUMP INHIBITOR; RANITIDINE; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; SUCRALFATE; TEA TREE OIL; TERFENADINE; TRIAZOLAM; UNCLASSIFIED DRUG; UNINDEXED DRUG; VORICONAZOLE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; CANDIDIASIS; DRUG EFFICACY; DRUG FORMULATION; DRUG INDUCED DISEASE; DRUG SAFETY; ESOPHAGITIS; GASTROINTESTINAL TOXICITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAVAGINAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MOUTH INFECTION; MYCOSIS; ORAL DRUG ADMINISTRATION; THRUSH; TOPICAL DRUG ADMINISTRATION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANTIFUNGAL AGENTS; CANDIDIASIS, ORAL; DRUG RESISTANCE, MICROBIAL; ESOPHAGITIS; FORECASTING; HIV INFECTIONS; HUMANS;

EID: 0032919163     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.19.1.76.30509     Document Type: Article

References (122)

1. Odds FC. Candida and candidosis. A review and bibliography. London: Baillière Tindall, 1988.
2. Kleinegger CL, Lockhart SR, Vargas K, Soll DR. Frequency, intensity, species, and strains of oral Candida vary as a function of host age. J Clin Microbiol 1996;34:2246-54.
3. Johnston RD, Chick EW, Johnston NS, Jarvis MA. Asymptomatic quantitative increase of Candida albicans in the oral cavity: predisposing conditions. South Med J 1967;60:1244-7.
4. Stenderup A, Pedusen GT. Yeasts of human origin. Acta Pathol Microbiol Scand 1962;54:462-72.
5. Mackenzie DWR. Yeast from human sources. Sabouraudia 1962;1:8-15.
6. van't Wout JW. Fluconazole treatment of candidal infections caused by non-albicans Candida species. Eur J Clin Microbiol Infect Dis 1996;15:238-42.
7. Barchiesi F, Morbiducci V, Ancarani F, Scalise G. Emergence of oropharyngeal candidiasis caused by non-albicans species of Candida in HIV-infected patients. Eur J Epidemiol 1993;9:455-6.
8. Boerlin P, Boerlin-Petzold F, Goudet J, et al. Candida albicans oral isolates from human immunodeficiency virus-infected patients by multilocus enzyme electrophoresis and DNA fingerprinting. J Clin Microbiol 1996;34:1235-48.
9. Betta PG. Pathology of some of the opportunistic infections in acquired immune deficiency syndrome (AIDS). Pathologica 1985;77:67-75.
10. Chandler FW. Pathology of the mycoses in patients with the acquired immune deficiency syndrome (AIDS). Curr Topics Med Mycol 1985;1:1-23.
11. Jaffe HW, Bregman DJ, Selik RM. Acquired immune deficiency syndrome in the United States: the first 1,000 cases. J Infect Dis 1983;148:339-45.
12. Stenderup A, Schonheyder H. Mycoses complicating AIDS. Microbiol Sci 1984;1:219-23.
13. Melbye M, Schonheyder H, Kesters L, et al. Carriage of oral Candida albicans associated with a high number of circulating suppressor T lymphocytes [letter]. J Infect Dis 1985;152: 1356-7.
14. Schonheyder H, Melbye M, Biggar RJ, Ebbesen P, Newland CY, Stenderup A. Oral yeast flora and antibodies to Candida albicans in homosexual men. Mykosen 1984;27:539-44.
15. 2 enhances and gamma interferon inhibits germ tube formation in Candida albicans. Infect Immunol 1990;58:260-2.
16. Hippocrates CA, Adams F. Epidemics, book 3. Baltimore: Williams & Wilkins, 1939.
17. Coker RJ, Fisher M, Tomlinson DR. Management of mycoses associated with HIV disease. Int J STD AIDS 1995;6:408-12.
18. Silverman S Jr, Gallo JW, McKnight ML, Mayer P, deSanz S, Tan MM. Clinical characteristics and management responses in 85 HIV-infected patients with oral candidiasis. Oral Surg Oral Med Oral Pathol 1996;82:402-7.
19. Greenspan D. Treatment of oropharyngeal candidiasis in HIV-positive patients. J Am Acad Dermatol 1994;31:S51-5.
20. Feigal DW, Katz MH, Greenspan D, et al. The prevalence of oral lesions in HIV-infected homosexual and bisexual men: three San Francisco epidemiological cohorts. AIDS 1991;5:519-25.
21. Powderly WG, Robinson K, Keath EJ. Molecular typing of Candida albicans isolated from oral lesions of HIV-infected individuals. AIDS 1992;6:81-4.
22. Darouiche RO. Oropharyngeal and esophageal candidiasis in immunocompromised patients: treatment issues. Clin Infect Dis 1998;26:259-74.
23. Glatt AE, Chirgwin K, Landesman SH. Treatment of infections associated with human immunodeficiency virus. N Engl J Med 1988;318:1439-48.
24. Selik RM, Starcher ET, Curran JW. Opportunistic diseases reported in AIDS patients: frequencies, associations, and trends. AIDS 1987;1:175-82.
25. Vazquez J, Lynch M, Boikov D, Sobel JD. Incidence of in vitro antifungal cross resistance among fluconazole-resistant Candida albicans and Torulopsis glabrata isolates. [abstr]. In: Proceedings of the 33rd annual meeting of the Infectious Disease Society of America. Washington, DC: Infectious Disease Society of America, 1995:102.
26. Kozinn PJ, Taschdjian CL, Dragutsky D, et al. Therapy of oral thrush: a comparative evaluation of gentian violet, mycostatin and amphotericin B. Monogr Ther 1957;2:16-24.
27. Pons V, Greenspan D, Lozada-Nur F, et al. Oropharyngeal candidiasis in patients with AIDS: randomized comparison of fluconazole versus nystatin oral suspensions. Clin Infect Dis 1997;24:1204-7.
28. Quintiliani R, Owens NJ, Quercia RA, Klimek JJ, Nightingale CH. Treatment and prevention of oropharyngeal candidiasis. Am J Med 1994;77(suppl 4D):44-8.
29. Yap BS, Bodey GP. Oropharyngeal candidiasis treated with a troche form of clotrimazole. Arch Intern Med 1979;139: 656-7.
30. Shectman LB, Funaro L, Robin T, Bottone EJ, Cuttner J. Clotrimazole treatment of oral candidiasis in patients with neoplastic disease. Am J Med 1984;76:91-4.
31. Pons V, Greenspan D, Debruin M, et al. Therapy for oropharyngeal candidiasis in HIV-infected patients: a randomized, prospective multicenter study of oral fluconazole versus clotrimazole troches. J Acquir Immune Defic Syndr 1993;6:1311-16.
32. Hughes WT, Bartley DL, Patterson GG, Tufenkeji H. Ketoconazole and candidiasis: a controlled study. J Infect Dis 1983;147:1060-3.
33. Como JA, Dismukes WE. Oral azole drugs as systemic antifungal therapy. N Engl J Med 1994;330:263-72.
34. Fromtling RA. Overview of medically important antifungal azole derivatives. Clin Microbiol Rev 1988;1:187-217.
35. DeWit S, Weerts D, Goossens H, Clumeck N. Comparison of fluconazole and ketoconazole for oropharyngeal candidiasis in AIDS. Lancet 1989;1:746-8.
36. Piscitelli SC, Flexner C, Minor JR, Polis MA, Masur H. Drug interactions in patients infected with human immunodeficiency virus. Clin Infect Dis 1996;23:685-93.
37. Honig PK, Wortham DC, Zamani K, Conner DP, Mullin JC, Cantilena LR. Terfenadine-ketoconazole interaction. Pharmacokinetic and electrocardiographic consequences. JAMA 1993;269:1513-18.
38. Meyer JM, Rodvold KA. Drug biotransformation by the cytochrome P-450 enzyme system. Infect Med 1996;June: 452-64.
39. Murray PA, Koletar SL, Mallegol I, Wu J, Moskovitz BL. Itraconazole oral solution versus clotrimazole troches for the treatment of oropharyngeal candidiasis in immunocompromised patients. Clin Ther 1997;19:471-80.
40. Hay RJ. Overview of studies of fluconazole in oropharyngeal candidiasis. Rev Infect Dis 1990;12(suppl 3):S334-7.
41. Meunier F, Aoun M, Gerard M. Therapy of oropharyngeal candidiasis in the immunocompromised host: a randomized double-blind study of fluconazole vs ketoconazole. Rev Infect Dis 1990;12(suppl 3):S364-8.
42. Koletar SL, Russell JA, Fass RJ, Plouffe JF. Comparison of oral fluconazole and clotrimazole troches as treatment for oral candidiasis in patients infected with human immunodeficiency virus. Antimicrob Agents Chemother 1990;34:2267-8.
43. Dupont B, Drouhet E. Fluconazole in the management of oropharyngeal candidosis in a predominantly HIV antibody-positive group of patients. J Med Vet Mycol 1988;26:67-71.
44. Zimmermann T, Yeates RA, Laufen H, Pfaff G, Wildfeuer A. Influence of concomitant food intake on the oral absorption of two triazole antifungal agents, itraconazole and fluconazole. Eur J Clin Pharmacol 1994;46:147-50.
45. Van de Velde VJS, Van Peer AP, Heykants JJP, et al. Effect of food on the pharmacokinetics of a new hydroxypropyl-β-cyclodextrin formulation of itraconazole. Pharmacotherapy 1996;16:424-8.
46. Barone JA, Moskovitz BL Guarnieri J, et al. Food interaction and steady-state pharmacokinetics of itraconazole oral solution in healthy volunteers. Pharmacotherapy 1998;18: 295-301.
47. Graybill JR, Vazquez J, Darouiche RO, et al. Itraconazole oral solution: a novel and effective treatment for oropharyngeal candidiasis in HIV/AIDS patients. Am J Med 1998;104:33-9.
48. Janssen Pharmaceutica. Data on file. Beerse, Belgium;1993.
49. Hostetler JS, Hanson LH, Stevens DA. Effect of cyclodextrin on the pharmacology of antifungal oral azoles. Antimicrob Agents Chemother 1992;36:477-80.
50. Kowalsky SF, Dixon DM. Fluconazole: a new antifungal agent. Clin Pharm 1991;10:179-94.
51. Tucker RM, Denning DW, Hanson LH, et al. Interactions of azoles with rifampin, phenytoin, and carbamazepine: in vitro and clinical observations. Clin Infect Dis 1992;14:165-74.
52. Horsburgh CR Jr, Kirkpatrick CH. Long-term therapy of chronic mucocutaneous candidiasis with ketoconazole: experience with 21 patients. Am J Med 1983;74(suppl 1B):23-9.
53. Chavanet P, Lopez J, Grappin M, et al. Cross-sectional study of the susceptibility of Candida isolates to antifungal drugs and in vitro-in vivo correlation in HIV-infected patients. AIDS 1994;8:945-50.
54. Quereda C, Polanco AM, Giner C, et al. Correlation between in vitro resistance to fluconazole and clinical outcome of oropharyngeal candidiasis in HIV-infected patients. Eur J Clin Microbiol Infect Dis 1996;15:30-7.
55. Schuman P, Capps L, Peng G, et al. Weekly fluconazole for the prevention of mucosal candidiasis in women with HIV infection. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1997;126:689-96.
56. Maenza JR, Merz WG, Romagnoli MJ, Keruly JC, Moore RD, Gallant JE. Infection due to fluconazole-resistant Candida in patients with AIDS: prevalence and microbiology. Clin Infect Dis 1997;24:28-34.
57. Dronda F, Alonso-Sanz M, Laguna F, et al. Mixed oropharyngeal candidiasis due to Candida albicans and non-albicans Candida strains in HIV-infected patients. Eur J Clin Microbiol Infect Dis 1996;15:446-52.
58. Chryssanthou E, Torssandeer J, Petrini B. Oral Candida albicans isolates with reduced susceptibility to fluconazole in Swedish HIV-infected patients. Scand J Infect Dis 1995;27:391-5.
59. Tavitian A, Raufman J-P, Rosenthal LE, Weber J, Webber CA, Dincsoy HP. Ketoconazole-resistant Candida esophagitis in patients with acquired immunodeficiency syndrome. Gastroenterology 1986;90:443-5.
60. Barlett JG. 1998 medical management of HIV infection. Baltimore: Port City Press, 1998.
61. Stevens DA, Greene I, Lang OS. Thrush can be prevented in patients with acquired immunodeficiency syndrome and the acquired immunodeficiency syndrome-related complex. Randomized, double-blind, placebo-controlled study of 100-mg oral fluconazole daily. Arch Intern Med 1991;151:2458-64.
62. Leen CLS, Dunbar EM, Ellis ME, Mandal BK. Once-weekly fluconazole to prevent recurrence of oropharyngeal candidiasis in patients with AIDS and AlDS-related complex: a double-blind placebo-controlled study. J Infect 1990;21:55-60.
63. Powderly WG, Finkelstein DM, Feinberg J, et al. A randomized trial comparing fluconazole with clotrimazole troches for the prevention of fungal infections in patients with advanced human immunodeficiency virus infection. N Engl J Med 1995;332:700-5.
64. Manfredi R, Mastroianni A, Coronado OV, Chiodo F. Fluconazole as prophylaxis against fungal infection in patients with advanced HIV infection. Arch Intern Med 1997;157:64-9.
65. Moore RD, Chaisson RE. Natural history of opportunistic disease in an HIV-infected urban clinical cohort. Ann Intern Med 1996;124:633-42.
66. Dupont B, Denning DW, Marriot D, Sugar A, Viviani MA, Sirisanthana T. Mycosis in AIDS. J Med Vet Mycol 1994;32(suppl):65-77.
67. Jensen KB, Stenderup A, Thomsen JB. Esophageal moniliasis in malignant neoplastic disease. Acta Med Scand 1964;175:455-9.
68. Kodsi BE, Wickremesinghe PC, Kozinn PJ, Iswara K, Goldberg PK. Candida esophagitis: a prospective study of 27 cases. Gastroenterology 1976;71:715-19.
69. Scott BB, Jenkins D. Gastro-oesophageal candidiasis. Gut 1982;23:137-9.
70. Clotet B, Grifol M, Parro B, et al. Asymptomatic esophageal candidiasis in acquired-immunodeficiency-syndrome-related complex [letter]. Ann Intern Med 1986;105:145.
71. Ginsburg CH, Braden GL, Tauber AI, Trier JS. Oral clotrimazole in the treatment of esophageal candidiasis. Am J Med 1981;71:891-5.
72. Rutgeerts L, Verhaegen H. Intravenous miconazole in the treatment of chronic esophageal candidiasis. Gastroenterology 1977;72:316-18.
73. Fazio RA, Wickremesinghe PC, Arsura EL. Ketoconazole treatment of Candida esophagitis: a prospective study of 12 cases. Am J Gastroenterol 1983;78:261-4.
74. Sugar AM, Alsip SG, Galgiani JN, et al. Pharmacology and toxicity of high-dose ketoconazole. Antimicrob Agents Chemother 1987;31:1874-8.
75. De Wit S, Urbain D, Rahir F, Weerts D, Clumeck N. Efficacy of oral fluconazole in the treatment of AIDS associated oesophageal candidiasis. Eur J Clin Microbiol Infect Dis 1991;10:503-5
76. Laine L, Dretler RH, Conteas CN, et al. Fluconazole compared with ketoconazole for the treatment of Candida esophagitis in AIDS. A randomized trial. Ann Intern Med 1992;117:655-60.
77. Laine L, Rabeneck L. Prospective study of fluconazole suspension for the treatment of oesophageal candidiasis in patients with AIDS. Aliment Pharmacol Ther 1995;9:553-6.
78. Wilcox CM, Darouiche RO, Laine L, Moskovitz BL, Mallegol I, Wu J. A randomized, double-blind comparison of itraconazole oral solution and fluconazole tablets in the treatment of esophageal candidiasis. J Infect Dis 1997;176:227-32.
79. Barbaro G, Barbarini G, Di Lorenzo G. Fluconazole compared with itraconazole in the treatment of esophageal candidiasis in AIDS patients: a double-blind, randomized, controlled clinical study. Scand J Infect Dis 1995;27:613-17.
80. Barbaro G, Barbarini G, Calderon W, Grisorio B, Alcini P, DiLorenzo G. Fluconazole versus itraconazole for Candida esophagitis in acquired immunodeficiency syndrome. Gastroenterology 1996;111:1169-77.
81. Medoff G, Dismukes WE, Meade RH III, Moses JM. A new therapeutic approach to Candida infections. A preliminary report. Arch Intern Med 1972;130:241-5.
82. Bennett JE. Diagnosis and management of candidiasis in the immunosuppressed host. Scand J Infect Dis Suppl 1978;16:83-6.
83. Lake DE, Kunzweiler J, Beer M, Buell DN, Islam MZ. Fluconazole versus amphotericin B in the treatment of esophageal candidiasis in cancer patients. Chemotherapy 1996;42:308-14.
84. Barbaro G, Barbarini G, Di Lorenzo G. Fluconazole vs flucytosine in the treatment of esophageal candidiasis in AIDS patients: a double-blind, placebo controlled study. Endoscopy 1995;27:377-83.
85. Reef SE, Mayer KH. Opportunistic candidal infections in patients infected with human immunodeficiency virus: prevention issues and priorities. Clin Infect Dis 1995;21(suppl 1):S99-102.
86. Koletar SL, Weed HG, Raimundo MB. Thrush unresponsive to treatment with fluconazole in HIV-infected patients [abstr]. Presented at the 1st national conference on human retroviruses, Washington, DC, December 12-16, 1993.
87. Vazquez JA, Sobel JD. Epidemiologic overview of resistance to oral antifungal agents in the immunocompromised host. Excerpta Medica Abstr Journals. Amsterdam: Elsevier Science B.V., 1997:1-11.
88. National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of yeasts: Wayne, PA: Author, 1997.
89. Rex JH, Pfaller MA, Galgiani JN, et al. Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in-vitro correlation data for fluconazole, itraconazole, and Candida infections. Clin Infect Dis 1997;24:235-47.
90. Cameron ML, Schell WA, Bruch S, Bartlett JA, Waskin HA, Perfect JR. Correlation of in vitro fluconazole resistance of Candida isolates in relation to therapy and symptoms of individuals seropositive for human immunodeficiency virus type 1. Antimicrob Agents Chemother 1993;37:2449-53.
91. Revankar SG, Dib OP, Kirkpatrick WR, et al. Clinical evaluation and microbiology of oropharyngeal infection due to fluconazole-resistant Candida in human immunodeficiency virus-infected patients. Clin Infect Dis 1998;26:960-3.
92. Fox R, Neal KR, Leen CLS, Ellis ME, Mandal BK. Fluconazole-resistant Candida in AIDS [letter]. J Infect Dis 1991;22:201-4.
93. Kitchen VS, Savage M, Harris JR. Candida albicans resistance in AIDS [letter]. J Infect Dis 1991;22:204-5.
94. Horn CA, Washburn RG, Givner LB, Peacock JE Jr, Pegram PS. Azole-resistant oropharyngeal and esophageal candidiasis in patients with AIDS. AIDS 1995;9:533-4.
95. Maenza JR, Keruly JC, Moore RD, Chaisson RE, Merz WG, Gallant JE. Risk factors for fluconazole-resistant candidiasis in human immunodeficiency virus-infected patients. J Infect Dis 1996;173:219-25.
96. McCarthy GM, Mackie ID, Koval J, Sandhu HS, Daley TD. Factors associated with increased frequency of HIV-related oral candidiasis. J Oral Pathol Med 1991;20:332-6.
97. Newman SL, Flanigan TP, Fisher A, Rinaldi MG, Stein M, Vigilante K. Clinically significant mucosal candidiasis resistant to fluconazole treatment in patients with AIDS. Clin Infect Dis 1994;19:684-6.
98. Moran GP, Sullivan DJ, Henman MC, et al. Antifungal drug susceptibilities of oral Candida dubliniensis isolates from human immunodeficiency virus (HIV)-infected and non-HIV-infected subjects and generation of stable fluconazole-resistant derivatives in vitro. Antimicrob Agents Chemother 1997;41:617-23.
99. St. Germain G, Dion C, Espinel-Ingroff A, Ratelle J, de Repentigny L. Ketoconazole and itraconazole susceptibility of Candida albicans isolated from patients infected with HIV. J Antimicrob Chemother 1995;36:109-18.
100. Valentin A, Le Guennec R, Rodriguez E, Reynes J, Mallie M, Bastide J-M. Comparative resistance of Candida albicans clinical isolates to fluconazole and itraconazole in vitro and in vivo in a murine model. Antimicrob Agents Chemother 1996;40:1342-5.
101. Martins M, Rex JH. Fluconazole suspension for oropharyngeal candidiasis unresponsive to tablets [letter]. Ann Intern Med 1997;126:332-3.
102. Philips P, Zemcov J, Mahmood W, Montaner JSG, Craib K, Clarke AM. Itraconazole cyclodextrin solution for fluconazole-refractory oropharyngeal candidiasis in AIDS: correlation of clinical response with in vitro susceptibility. AIDS 1996;10:1369-76.
103. Eichel M, Just-Nübling G, Helm EB, Stille W. Itraconazole suspension in the treatment of HIV-infected patients with fluconazole-resistant oropharyngeal candidiasis and esophagitis [in German]. Mycoses 1996;39(suppl 1):102-6.
104. Fessel WJ, Merrill KW, Ward DJ, et al. Itraconazole oral solution for the treatment of fluconazole-refractory oropharyngeal candidiasis in HIV-positive patients [abstr]. In: Proceedings of the 4th conference on retroviruses and opportune infections. Alexandria, VA: Foundation for Retrovirology, 1997:124.
105. Cartledge JD, Midgley J, Gazzard BG. Ilraconazole cyclodextrin solution: the role of in vitro susceptibility testing in predicting successful treatment of HIV-related fluconazole-resistant and fluconazole-susceptible oral candidosis. AIDS 1997;11:163-8.
106. Coppola S, Angarano G, Montagna MT, et al. Efficacy of itraconazole in treating AIDS-associated infections due to Candida krusei. Eur J Epidemiol 1995;11:243-4.
107. de Repentigny L, Ratelle J, and the Human Immunodeficiency Virus Itraconazole Ketoconazole Project Group. Comparison of itraconazole and ketoconazole in HIV-positive patients with oropharyngeal or esophageal candidiasis. Chemotherapy 1996;42:374-83.
108. Baily GG, Perry, FM, Denning DW, Mandal BK. Fluconazole-resistant candidosis in an HIV cohort. AIDS 1994;8:787-92.
109. Nguyen MT, Weiss PJ, LaBarre RC, Miller LK, Oldfield EC, Wallace MR. Orally administered amphotericin B in the treatment of oral candidiasis in HIV-infected patients caused by azole-resistant Candida albicans. AIDS 1996;10:1745-7.
110. Dewsnup DH, Stevens DA. Efficacy of oral amphotericin B in AIDS patients with thrush clinically resistant to fluconazole. J Med Vet Mycol 1994;32:389-93.
111. Zingman BS. Treatment of mucosal candidiasis in HIV-infected patients. J Mycol Med 1996;6:3-11.
112. Brajtburg J, Powderly WG, Kobayashi GS, Medoff G. Amphotericin B; delivery systems. Antimicrob Agents Chemother 1990;34:381-4.
113. Anaissie EJ, Kontoyiannis DP, Huls C, et al. Safety, plasma concentrations, and efficacy of high-dose fluconazole in invasive mold infections. J Infect Dis 1995;172:599-602.
114. Ruhnke M, Schmidt-Westhausen A, Trautmann M. In vitro activities of voriconazole (UK-109,496) against fluconazole-susceptible and -resistant Candida albicans isolates from oral cavities of patients with human immunodeficiency virus infection. Antimicrob Agents Chemolher 1997;41:575-7.
115. Law D, Denning DW. In vitro activity of Schering 56592, compared with fluconazole and itraconazole against Candida spp [abstr]. In: Proceedings of the 36th international conference on antimicrob agents and chemotherapy. Washington, DC: American Society for Microbiology, 1996:115.
116. Vazquez J, Lynch M, Boikov D, Sobel JD. In vitro activity of a new pneumocandin antifungal, L-743,872, against azole-susceptible and -resistant Candida species. Antimicrob Agents Chemother 1997;41:1612-14.
117. Zingman B. Resolution of refractory AIDS-related mucosal candidiasis after initiation of didanosine plus saquinavir [letter]. N Engl J Med 1996;334:1674-5.
118. Vecchiarelli A, Monari C, Baldelli F, et al. Beneficial effect of recombinant human granulocyte colony-stimulating factor on fungicidal activity of polymorphonuclear leukocytes from patients with AIDS. J Infect Dis 1995;171:1448-54
119. Bonfati P, Capetti A, De Micheli A, Milella AM, Rizzardini G. RuGM-CSF employment for resistant Candida infections in HIV disease [abstr]. Presented at the XI international conference on AIDS, Vancouver, BC, July 7-12, 1996.
120. Swindells S, Kleinschmidt DR, Hayes FA. Pilot study of adjunctive GM-CSF (yeast-derived) for fluconazole-resistant oral candidiasis in HIV-infection. Infect Dis Clin Pract 1997;6:278-9.
121. Vazquez JA, Gupta S, Villanueva A. Role of rhu-GM-CSF as adjunctive treatment of antifungal refractory oropharyngeal candidiasis in patients with AIDS. Eur J Clin Microbiol Infect Dis In press.
122. Jandourek A, Vaishampayan JK, Vazquez JA. Efficacy of melaleuca oral solution for the treatment of fluconazole refractory oral candidiasis in AIDS patients. AIDS 1998;12:1033-7.